AtriCure, Inc. Aktie News

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026. AtriCure will host an audio webcast at 4:30 p.m...

AtriCure, Inc. (ATRC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2025 and provided 2026 financial guidance. Preliminary, unaudited revenue for fourth quar...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming J.P. Morgan 44th Annual Healthcare Conference. AtriCure's management is scheduled to present on Wedn...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced successful first-in-human treatments using its novel dual energy platform that integrates Pulsed Field Ablation (PFA) with Advanced Radiofrequency Ablation ...

AtriCure Board of Directors member Sven Wehrwein sold 10,000 shares in the company on Nov. 24 and 25, 2025. The transaction was valued at nearly $377,000.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 37th Annual Healthcare Conference. AtriCure's management is scheduled to participate i...

AtriCure, Inc. ( ATRC ) UBS Global Healthcare Conference 2025 November 10, 2025 2:00 PM EST Company Participants Angela Wirick - Chief Financial Officer Michael H. Carrel - CEO, President & Director Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division Well, good afternoon, everyone.